Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PPARG_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PPARG_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPARG_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPARG_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PPARG_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657314 | Thyroid | ATC | histone acetylation | 89/6293 | 152/18723 | 2.31e-10 | 6.72e-09 | 89 |
GO:000042223 | Thyroid | ATC | autophagy of mitochondrion | 55/6293 | 81/18723 | 2.88e-10 | 8.17e-09 | 55 |
GO:006172623 | Thyroid | ATC | mitochondrion disassembly | 55/6293 | 81/18723 | 2.88e-10 | 8.17e-09 | 55 |
GO:004828512 | Thyroid | ATC | organelle fission | 229/6293 | 488/18723 | 4.79e-10 | 1.29e-08 | 229 |
GO:0070997210 | Thyroid | ATC | neuron death | 176/6293 | 361/18723 | 1.43e-09 | 3.57e-08 | 176 |
GO:000989529 | Thyroid | ATC | negative regulation of catabolic process | 159/6293 | 320/18723 | 1.61e-09 | 3.99e-08 | 159 |
GO:000756829 | Thyroid | ATC | aging | 166/6293 | 339/18723 | 2.79e-09 | 6.60e-08 | 166 |
GO:0051054110 | Thyroid | ATC | positive regulation of DNA metabolic process | 107/6293 | 201/18723 | 7.10e-09 | 1.54e-07 | 107 |
GO:0010821112 | Thyroid | ATC | regulation of mitochondrion organization | 82/6293 | 144/18723 | 7.15e-09 | 1.54e-07 | 82 |
GO:190121428 | Thyroid | ATC | regulation of neuron death | 156/6293 | 319/18723 | 9.30e-09 | 1.96e-07 | 156 |
GO:003105616 | Thyroid | ATC | regulation of histone modification | 85/6293 | 152/18723 | 1.23e-08 | 2.55e-07 | 85 |
GO:004259424 | Thyroid | ATC | response to starvation | 103/6293 | 197/18723 | 4.59e-08 | 8.31e-07 | 103 |
GO:001969328 | Thyroid | ATC | ribose phosphate metabolic process | 184/6293 | 396/18723 | 5.87e-08 | 1.05e-06 | 184 |
GO:007145325 | Thyroid | ATC | cellular response to oxygen levels | 94/6293 | 177/18723 | 6.62e-08 | 1.17e-06 | 94 |
GO:000915029 | Thyroid | ATC | purine ribonucleotide metabolic process | 172/6293 | 368/18723 | 9.58e-08 | 1.64e-06 | 172 |
GO:000925928 | Thyroid | ATC | ribonucleotide metabolic process | 178/6293 | 385/18723 | 1.47e-07 | 2.39e-06 | 178 |
GO:0031667210 | Thyroid | ATC | response to nutrient levels | 212/6293 | 474/18723 | 2.37e-07 | 3.70e-06 | 212 |
GO:000914427 | Thyroid | ATC | purine nucleoside triphosphate metabolic process | 53/6293 | 88/18723 | 2.75e-07 | 4.20e-06 | 53 |
GO:007252128 | Thyroid | ATC | purine-containing compound metabolic process | 189/6293 | 416/18723 | 2.83e-07 | 4.29e-06 | 189 |
GO:003629425 | Thyroid | ATC | cellular response to decreased oxygen levels | 85/6293 | 161/18723 | 3.86e-07 | 5.65e-06 | 85 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPARG | SNV | Missense_Mutation | | c.724C>G | p.Leu242Val | p.L242V | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-A2-A0YC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
PPARG | SNV | Missense_Mutation | rs140204299 | c.1154N>A | p.Arg385Gln | p.R385Q | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | rs777334819 | c.235N>A | p.Glu79Lys | p.E79K | P37231 | protein_coding | tolerated_low_confidence(0.26) | benign(0.039) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
PPARG | SNV | Missense_Mutation | | c.724C>G | p.Leu242Val | p.L242V | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-OL-A66H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | novel | c.489N>G | p.Phe163Leu | p.F163L | P37231 | protein_coding | deleterious(0) | possibly_damaging(0.535) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
PPARG | insertion | Frame_Shift_Ins | novel | c.549_550insA | p.Ser186LysfsTer2 | p.S186Kfs*2 | P37231 | protein_coding | | | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PPARG | insertion | Nonsense_Mutation | novel | c.64_65insTGTTAGTAATGTAGGGATG | p.Ser22LeufsTer5 | p.S22Lfs*5 | P37231 | protein_coding | | | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | | c.181N>C | p.Asp61His | p.D61H | P37231 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.969) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PPARG | SNV | Missense_Mutation | | c.1477N>T | p.Leu493Phe | p.L493F | P37231 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-G4-6307-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD |
PPARG | deletion | Frame_Shift_Del | | c.550delN | p.Ser186ValfsTer47 | p.S186Vfs*47 | P37231 | protein_coding | | | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | GTF505 | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | BENSULIDE | BENSULIDE | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135650496 | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | SHINPTEROCARPIN | SHINPTEROCARPIN | 20022509 |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | TREPROSTINIL | TREPROSTINIL | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | modulator | CHEMBL490029 | MK-0533 | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | DICHLOROPHEN | DICHLOROPHEN | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | FLUDIOXONIL | FLUDIOXONIL | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | ETHYL EICOSAPENTAENOIC ACID | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | AMORFRUTIN A | AMORFRUTIN A | 25938459 |